Mariangela Succoio

Dr. Mariangela Succoio

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MSMariangela Succoio
Mariangela Succoio
RSRosa Sacchettini
Rosa Sacchettini
ARAlessandro Rossi
Alessandro Rossi
GPGiancarlo Parenti
Giancarlo Parenti
Margherita RuoppoloMargherita Ruoppolo
Margherita Ruoppolo
Galactosemia is an inborn disorder of carbohydrate metabolism characterized by the inability to metabolize galactose, a sugar contained in milk (the main source of nourishment for infants), and convert it into glucose, the sugar used by the body as the primary source of energy. Galactosemia is an autosomal recessive genetic disease that can be diagnosed at birth, even in the absence of symptoms, with newborn screening by assessing the level of galactose and the GALT enzyme activity, as GALT defect constitutes the most frequent cause of galactosemia. Currently, galactosemia cannot be cured, but only treated by means of a diet with a reduced content of galactose and lactose. Although the diet is able to reverse the neonatal clinical picture, it does not prevent the development of long-term complications. This review provides an overview of galactose metabolism, molecular genetics, newborn screening and therapy of galactosemia. Novel treatments for galactosemia currently being investigated in (pre)clinical studies and potentially able to prevent long-term complications are also presented.

13 May 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MCMarika Comegna
Marika Comegna
MSMariangela Succoio
Mariangela Succoio
MNMarco Napolitano
Marco Napolitano
MVMonica Vitale
Monica Vitale
CDChiara D'Ambrosio
Chiara D'Ambrosio
Raffaella FaraonioRaffaella Faraonio
Raffaella Faraonio
Cellular senescence is a permanent cell cycle arrest triggered by different stimuli. We recently identified up‐regulation of microRNA (miR)‐494 as a component of the genetic program leading to senescence of human diploid IMR90 fibroblasts. Here, we used 2‐dimensional differential gel electrophoresis (2D‐DIGE) coupled to mass spectrometry to profile protein expression changes induced by adoptive overexpression of miR‐494 in IMR90 cells. miR‐494 induced robust perturbation of the IMR90 proteome by significantly ( P <0.05) down‐regulating a number of proteins. Combination of mass spectrometry‐based identification of down‐regulated proteins and bioinformatic prediction of the miR‐494 binding sites on the relevant mRNAs identified 26 potential targets of miR‐494. Among them, computational analysis identified 7 potential evolution‐conserved miR‐494 targets. Functional miR‐494 binding sites were confirmed in 3'‐untranslated regions (UTRs) of 4 of them [heterogeneous nuclear ribonucleoprotein A3 (hnRNPA3), protein disulfide isomerase A3 (PDIA3), UV excision repair protein RAD23 homolog B (RAD23B), and synaptotagmin‐binding cytoplasmic RNA‐interacting protein (SYNCRIP)/heterogeneous nuclear ribonucleoprotein Q (hnRNPQ)]. Their reduced expression correlated with miR‐494 up‐regulation in senescent cells. RNA interference‐mediated knockdown of hnRNPA3 and, to a lesser extent, RAD23B mirrored the senescent phenotype induced by miR‐494 overexpression, blunting cell proliferation and causing up‐regulation of SA‐β‐galactosidase and DNA damage. Ectopic expression of hnRNPA3 or RAD23B slowed the appearance of the senescent phenotype induced by miR‐494. Overall, these findings identify novel miR‐494 direct targets that are involved in cellular senescence.—Comegna, M., Succoio, M., Napolitano, M., Vitale, M., D'Ambrosio, C., Scaloni, A., Passaro, F., Zambrano, N., Cimino, F., Faraonio, R. Identification of miR‐494 direct targets involved in senescence of human diploid fibroblasts. FASEB J. 28, 3720–3733 (2014). www.fasebj.org

6 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MNMarco Napolitano
Marco Napolitano
MCMarika Comegna
Marika Comegna
MSMariangela Succoio
Mariangela Succoio
ELEleonora Leggiero
Eleonora Leggiero
LPLucio Pastore
Lucio Pastore
FPFabiana Passaro
Fabiana Passaro
In the last decades, cellular senescence is viewed as a complex mechanism involved in different processes, ranging from tumor suppression to induction of age-related degenerative alterations. Senescence-inducing stimuli are myriad and, recently, we and others have demonstrated the role exerted by microRNAs in the induction and maintenance of senescence, by the identification of a subset of Senescence-Associated microRNAs (SAmiRs) up-regulated during replicative or stress-induced senescence and able to induce a premature senescent phenotype when over-expressed in human primary cells. With the intent to find novel direct targets of two specific SAmiRs, SAmiR-494 and -486-5p, and cellular pathways which they are involved in, we performed a comparative analysis of gene expression profiles available in literature to select genes down-regulated upon replicative senescence of human primary fibroblasts. Among them, we searched for SAmiR’s candidate targets by analyzing with different target prediction algorithms their 3’UTR for the presence of SAmiR-binding sites. The expression profiles of selected candidates have been validated on replicative and stress-induced senescence and the targeting of the 3’UTRs was assessed by luciferase assay. Results allowed us to identify Cell Division Cycle Associated 2 (CDCA2) and Inhibitor of DNA binding/differentiation type 4 (ID4) as novel targets of SAmiR-494 and SAmiR-486-5p, respectively. Furthermore, we demonstrated that the over-expression of CDCA2 in human primary fibroblasts was able to partially counteract etoposide-induced senescence by mitigating the activation of DNA Damage Response.

28 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
DRDomenico Rendina
Domenico Rendina
LDLanfranco D'elia
Lanfranco D'elia
VAVeronica Abate
Veronica Abate
ARAndrea Rebellato
Andrea Rebellato
IBIlaria Buondonno
Ilaria Buondonno
Raffaella FaraonioRaffaella Faraonio
Raffaella Faraonio
The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.

4 October 2021 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ACAntonella Cardinale
Antonella Cardinale
SCSueva Cantalupo
Sueva Cantalupo
VLVito Alessandro Lasorsa
Vito Alessandro Lasorsa
AMAnnalaura Montella
Annalaura Montella
Flora CimminoFlora Cimmino
Flora Cimmino
Mario CapassoMario Capasso
Mario Capasso
The 10q24.33 locus is known to be associated with susceptibility to cutaneous malignant melanoma (CMM), but the mechanisms underlying this association have been not extensively investigated. We carried out an integrative genomic analysis of 10q24.33 using epigenomic annotations and in vitro reporter gene assays to identify regulatory variants. We found two putative functional single nucleotide polymorphisms (SNPs) in an enhancer and in the promoter of OBFC1, respectively, in neural crest and CMM cells, one, rs2995264, altering enhancer activity. The minor allele G of rs2995264 correlated with lower OBFC1 expression in 470 CMM tumors and was confirmed to increase the CMM risk in a cohort of 484 CMM cases and 1801 controls of Italian origin. Hi-C and chromosome conformation capture (3C) experiments showed the interaction between the enhancer-SNP region and the promoter of OBFC1 and an isogenic model characterized by CRISPR-Cas9 deletion of the enhancer-SNP region confirmed the potential regulatory effect of rs2995264 on OBFC1 transcription. Moreover, the presence of G-rs2995264 risk allele reduced the binding affinity of the transcription factor MEOX2. Biologic investigations showed significant cell viability upon depletion of OBFC1, specifically in CMM cells that were homozygous for the protective allele. Clinically, high levels of OBFC1 expression associated with histologically favorable CMM tumors. Finally, preliminary results suggested the potential effect of decreased OBFC1 expression on telomerase activity in tumorigenic conditions. Our results support the hypothesis that reduced expression of OBFC1 gene through functional heritable DNA variation can contribute to malignant transformation of normal melanocytes.